A Leadership Vacuum: How Empty Director Chairs at NIH and CDC Will Reshape American Public Health

The Current Crisis

The U.S. public health infrastructure is entering uncharted territory. Jay Bhattacharya, the controversial Director of the National Institutes of Health, has now assumed temporary leadership of the Centers for Disease Control and Prevention as well, creating an unprecedented dual-agency role. According to Article 1, this appointment has "renewed criticism of Bhattacharya's lack of leadership," with insiders reporting that he delegates most responsibilities at NIH to two top officials while focusing on public interviews—earning him the nickname "Podcast Jay." Meanwhile, Article 5 reveals a stunning leadership vacuum: of the 27 institutes and centers that comprise NIH, 16 were missing permanent directors as of mid-February 2026. All but two of these vacancies opened during President Trump's second term through "a combination of terminations, resignations and retirements." As Dr. Elias Zerhouni, former NIH director under George W. Bush, warned: "It's like going to battle with half your generals in place."

Key Trends and Signals

Several converging patterns suggest where this situation is heading: **1. The Propagandist-in-Chief Model**: Multiple sources characterize Bhattacharya's role as primarily communicative rather than administrative. Article 1 quotes NIH program officer Jenna Norton saying Bhattacharya "won't actually run the CDC. Just as he doesn't actually run NIH" and that his role "is largely as a propagandist." Former NIGMS director Jeremy Berg added that Bhattacharya can now "largely ignore the actual operations of two" agencies. **2. Strategic Leadership Hollowing**: The mass exodus of NIH institute directors appears systematic rather than coincidental. Article 5 notes that Dr. Lindsey Criswell's departure from the National Institute of Arthritis and Musculoskeletal and Skin Diseases was announced "effective immediately" in an internal email, suggesting involuntary separations are ongoing. **3. Midterm Political Calculations**: Article 3 reveals this restructuring is explicitly tied to electoral strategy, noting the Trump administration is seeking to "shake up HHS's leadership team ahead of the midterms" and "stabilize a department rattled by internal fights and controversial messages." **4. Public Health Crisis Backdrop**: Article 1 places these leadership changes in stark context: "preventable diseases like measles are roaring back under RFK Jr.'s deadly" policies, creating a dangerous confluence of leadership vacuum and public health emergency.

Predictions: What Happens Next

### Short-Term (1-3 Months) **More Institute Director Positions Will Empty**: The pattern of departures shows no signs of slowing. Expect at least 3-5 more NIH institute directors to leave—whether through pressure, resignation, or termination—bringing the total vacancies to around 20 of 27 positions. This will occur as the administration seeks ideologically aligned replacements who support its reshaping of research priorities. **Bhattacharya Will Remain in Dual Role Through Midterms**: Despite criticism, the dual-agency arrangement serves the administration's political purposes too well to change quickly. Bhattacharya's media-focused approach aligns with the "propagandist" role described by insiders, providing a credentialed medical voice to defend administration policies during the campaign season. **Acting Directors Will Make Consequential Decisions**: With permanent leadership absent, acting directors at NIH institutes will begin making significant policy and funding allocation decisions that would normally require permanent director approval. This creates both uncertainty and opportunity for policy changes to slip through with less scrutiny. ### Medium-Term (3-6 Months) **A Slate of Ideologically Aligned Appointments**: Following the midterm elections, expect a coordinated announcement of multiple new NIH institute directors simultaneously. These appointments will likely share Bhattacharya's and RFK Jr.'s skepticism of mainstream public health approaches, fundamentally reorienting NIH's research priorities away from traditional infectious disease and vaccine work. **Brain Drain Accelerates**: As new leadership takes hold, expect a secondary wave of departures among senior scientists and program officers who find themselves at odds with new priorities. Article 5's characterization of the situation as "unprecedented" suggests many career staff are already contemplating exits. **CDC Credibility Crisis Deepens**: With Bhattacharya splitting attention between two agencies and his documented skepticism of CDC's pandemic response, the agency's public health guidance will face increased scrutiny and declining public trust, particularly if measles or other preventable disease outbreaks worsen. ### Long-Term (6-12 Months) **Fundamental Reorientation of Research Funding**: The new leadership cohort will begin redirecting the NIH's $47 billion budget toward administration priorities, potentially de-emphasizing vaccine research, infectious disease preparedness, and traditional public health interventions in favor of alternative approaches. **Congressional Pushback and Legal Challenges**: The courts and Congress have already "managed to withstand the Trump administration's attempts to slash its budget and upend how it distributes grants," according to Article 5. Expect legislative attempts to codify protections for NIH's independence and potential legal challenges to appointment processes that bypass traditional scientific review. **International Scientific Isolation**: As U.S. public health agencies diverge from international scientific consensus, expect reduced collaboration with global health institutions and potential relocation of international researchers and trials away from U.S. institutions.

The Stakes

Kayla Hancock of Public Health Watch called Bhattacharya's expanded role "malpractice against the public health." Whether one agrees with that characterization or not, the unprecedented leadership vacuum at America's premier biomedical research institution, combined with a part-time CDC director during a period of resurgent preventable diseases, represents a pivotal moment. The decisions made—or not made—in the coming months will shape American public health infrastructure and research priorities for a generation. The question is no longer whether these agencies will change, but how dramatically, and whether the changes can be reversed by future administrations or will become the new normal for U.S. public health leadership.